Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tax Conditions Clear all
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Studying the Impacts of Higher Taxes and Bans on Electronic Cigarettes to Improve Public Health

NCT07581041
View directory record Official record
Conditions
Tobacco-Related Carcinoma
Interventions
Discrete Choice Study, Survey Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
15 Years and older
Enrollment
3,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tobacco/Nicotine Purchase Patterns Across SES

NCT06795997
View directory record Official record
Conditions
Smoking Behaviors, Smoking, Non-Tobacco Products, Smoking, Cigarette
Interventions
Tax Conditions, Control Condition
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years and older
Enrollment
663 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 2, 2026, 5:46 PM EDT
Active, not recruiting Phase 3 Interventional

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408
View directory record Official record
Conditions
Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions
Nab-paclitaxel 80 mg/m^2, Relacorilant 150 mg once daily (QD), Nab-paclitaxel 100 mg/m^2
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
44
States / cities
Phoenix, Arizona • Tucson, Arizona • Irvine, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 2, 2026, 5:46 PM EDT
Active, not recruiting Phase 3 Interventional

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
AZD0901, Ramucirumab+ paclitaxel, Paclitaxel, Docetaxel, Irinotecan, TAS-102, Apatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Mobile, Alabama • Tucson, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Results available

A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies

NCT02412722
View directory record Official record
Conditions
Non-hematologic Malignancy
Interventions
Sapanisertib, Paclitaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • Sarasota, Florida • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Sep 2, 2026, 5:46 PM EDT
Completed Not applicable Interventional

The Impact of Innovative Tax Proposals on Purchase Patterns

NCT05370313
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Market Price Condition (control), Tobacco Parity Tax Condition, Nicotine-Content Tax Condition, Harm-Reduction Tax Condition, Modified Risk Tobacco Product (MRTP) Tax Condition
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
21 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Buffalo, New York • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 2, 2026, 5:46 PM EDT
Recruiting Phase 2 Interventional

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

NCT06906341
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
Interventions
Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Not yet recruiting Not applicable Interventional

Effects of Tobacco Abuse Liability-dependent Taxes in the ETM

NCT07042373
View directory record Official record
Conditions
Cigarette Smoking Behavior
Interventions
Control, Product Category Score, Product Category Rank, Product Tiers
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
21 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Results available

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

NCT03154294
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
paclitaxel, TAK-228, TAK-117
Drug
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 2, 2026, 5:46 PM EDT
Recruiting Phase 2 Interventional

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07259317
View directory record Official record
Conditions
Adenocarcinoma, Carcinoma, Pancreatic Ductal
Interventions
Relacorilant, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Recruiting Not applicable Interventional

Effects of Tax Proposals and Cigarette Availability on Tobacco Purchasing

NCT07142668
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Harm Reduction Tax - Normal Nicotine Cigarettes Available, Harm Reduction Tax - Normal Nicotine Cigarettes Not Available, Modified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Available, Modified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Not Available, Nicotine Content Tax - Normal Nicotine Cigarettes Available, Nicotine Content Tax - Normal Nicotine Cigarettes Not Available, Tobacco Parity Tax - Normal Nicotine Cigarettes Available, Tobacco Parity Tax - Normal Nicotine Cigarettes Not Available
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
21 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Buffalo, New York • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Terminated Phase 1 Interventional Results available

Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

NCT03894540
View directory record Official record
Conditions
Solid Tumor
Interventions
IPN60090, pembrolizumab, paclitaxel, IPN60090 single administration
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Sep 2, 2026, 5:46 PM EDT